Literature DB >> 29474905

A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response.

Takayuki Hoshii1, Paolo Cifani2, Zhaohui Feng1, Chun-Hao Huang3, Richard Koche4, Chun-Wei Chen1, Christopher D Delaney1, Scott W Lowe5, Alex Kentsis2, Scott A Armstrong6.   

Abstract

MLL/SET methyltransferases catalyze methylation of histone 3 lysine 4 and play critical roles in development and cancer. We assessed MLL/SET proteins and found that SETD1A is required for survival of acute myeloid leukemia (AML) cells. Mutagenesis studies and CRISPR-Cas9 domain screening show the enzymatic SET domain is not necessary for AML cell survival but that a newly identified region termed the "FLOS" (functional location on SETD1A) domain is indispensable. FLOS disruption suppresses DNA damage response genes and induces p53-dependent apoptosis. The FLOS domain acts as a cyclin-K-binding site that is required for chromosomal recruitment of cyclin K and for DNA-repair-associated gene expression in S phase. These data identify a connection between the chromatin regulator SETD1A and the DNA damage response that is independent of histone methylation and suggests that targeting SETD1A and cyclin K complexes may represent a therapeutic opportunity for AML and, potentially, for other cancers.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DNA damage response; SETD1A; cyclin K; histone methyltransferase; leukemia; transcription

Mesh:

Substances:

Year:  2018        PMID: 29474905      PMCID: PMC6052445          DOI: 10.1016/j.cell.2018.01.032

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   66.850


  49 in total

1.  Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss.

Authors:  Yaroslava Ruzankina; Carolina Pinzon-Guzman; Amma Asare; Tony Ong; Laura Pontano; George Cotsarelis; Valerie P Zediak; Marielena Velez; Avinash Bhandoola; Eric J Brown
Journal:  Cell Stem Cell       Date:  2007-06-07       Impact factor: 24.633

2.  The H3K4 methyltransferase Setd1a is first required at the epiblast stage, whereas Setd1b becomes essential after gastrulation.

Authors:  Anita S Bledau; Kerstin Schmidt; Katrin Neumann; Undine Hill; Giovanni Ciotta; Ashish Gupta; Davi Coe Torres; Jun Fu; Andrea Kranz; A Francis Stewart; Konstantinos Anastassiadis
Journal:  Development       Date:  2014-03       Impact factor: 6.868

3.  Mll2 is required for H3K4 trimethylation on bivalent promoters in embryonic stem cells, whereas Mll1 is redundant.

Authors:  Sergei Denissov; Helmut Hofemeister; Hendrik Marks; Andrea Kranz; Giovanni Ciotta; Sukhdeep Singh; Konstantinos Anastassiadis; Hendrik G Stunnenberg; A Francis Stewart
Journal:  Development       Date:  2014-01-14       Impact factor: 6.868

4.  Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.

Authors:  Tinghu Zhang; Nicholas Kwiatkowski; Calla M Olson; Sarah E Dixon-Clarke; Brian J Abraham; Ann K Greifenberg; Scott B Ficarro; Jonathan M Elkins; Yanke Liang; Nancy M Hannett; Theresa Manz; Mingfeng Hao; Bartlomiej Bartkowiak; Arno L Greenleaf; Jarrod A Marto; Matthias Geyer; Alex N Bullock; Richard A Young; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2016-08-29       Impact factor: 15.040

5.  Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex.

Authors:  Hyungsoo Kim; Ji-Eun Lee; Eun-Jung Cho; Jun O Liu; Hong-Duk Youn
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

6.  Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression.

Authors:  Akihiko Yokoyama; Zhong Wang; Joanna Wysocka; Mrinmoy Sanyal; Deborah J Aufiero; Issay Kitabayashi; Winship Herr; Michael L Cleary
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

Review 7.  The Fanconi anaemia pathway: new players and new functions.

Authors:  Raphael Ceccaldi; Prabha Sarangi; Alan D D'Andrea
Journal:  Nat Rev Mol Cell Biol       Date:  2016-05-05       Impact factor: 94.444

8.  DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier.

Authors:  Margarida A Santos; Robert B Faryabi; Aysegul V Ergen; Amanda M Day; Amy Malhowski; Andres Canela; Masahiro Onozawa; Ji-Eun Lee; Elsa Callen; Paula Gutierrez-Martinez; Hua-Tang Chen; Nancy Wong; Nadia Finkel; Aniruddha Deshpande; Susan Sharrow; Derrick J Rossi; Keisuke Ito; Kai Ge; Peter D Aplan; Scott A Armstrong; André Nussenzweig
Journal:  Nature       Date:  2014-07-27       Impact factor: 49.962

9.  Visualizing spatiotemporal dynamics of multicellular cell-cycle progression.

Authors:  Asako Sakaue-Sawano; Hiroshi Kurokawa; Toshifumi Morimura; Aki Hanyu; Hiroshi Hama; Hatsuki Osawa; Saori Kashiwagi; Kiyoko Fukami; Takaki Miyata; Hiroyuki Miyoshi; Takeshi Imamura; Masaharu Ogawa; Hisao Masai; Atsushi Miyawaki
Journal:  Cell       Date:  2008-02-08       Impact factor: 41.582

10.  The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.

Authors:  Dalibor Blazek; Jiri Kohoutek; Koen Bartholomeeusen; Eric Johansen; Petra Hulinkova; Zeping Luo; Peter Cimermancic; Jernej Ule; B Matija Peterlin
Journal:  Genes Dev       Date:  2011-10-15       Impact factor: 11.361

View more
  35 in total

1.  SETD1A Methyltransferase Is Physically and Functionally Linked to the DNA Damage Repair Protein RAD18.

Authors:  Manal Alsulami; Nayla Munawar; Eugene Dillon; Giorgio Oliviero; Kieran Wynne; Mona Alsolami; Catherine Moss; Peadar Ó Gaora; Fergal O'Meara; David Cotter; Gerard Cagney
Journal:  Mol Cell Proteomics       Date:  2019-05-10       Impact factor: 5.911

2.  Tolerance of DNA Replication Stress Is Promoted by Fumarate Through Modulation of Histone Demethylation and Enhancement of Replicative Intermediate Processing in Saccharomyces cerevisiae.

Authors:  Faeze Saatchi; Ann L Kirchmaier
Journal:  Genetics       Date:  2019-05-13       Impact factor: 4.562

Review 3.  COMPASS and SWI/SNF complexes in development and disease.

Authors:  Bercin K Cenik; Ali Shilatifard
Journal:  Nat Rev Genet       Date:  2020-09-21       Impact factor: 53.242

4.  Transcriptional Changes following Cellular Knockdown of the Schizophrenia Risk Gene SETD1A Are Enriched for Common Variant Association with the Disorder.

Authors:  Darren Cameron; Derek J Blake; Nicholas J Bray; Matthew J Hill
Journal:  Mol Neuropsychiatry       Date:  2019-03-25

5.  Cross-talk between Lysine-Modifying Enzymes Controls Site-Specific DNA Amplifications.

Authors:  Sweta Mishra; Capucine Van Rechem; Sangita Pal; Thomas L Clarke; Damayanti Chakraborty; Sarah D Mahan; Joshua C Black; Sedona E Murphy; Michael S Lawrence; Danette L Daniels; Johnathan R Whetstine
Journal:  Cell       Date:  2018-07-26       Impact factor: 41.582

Review 6.  A chromatin perspective on metabolic and genotoxic impacts on hematopoietic stem and progenitor cells.

Authors:  Zhenhua Yang; Hao Jiang
Journal:  Cell Mol Life Sci       Date:  2020-04-21       Impact factor: 9.261

Review 7.  The complex activities of the SET1/MLL complex core subunits in development and disease.

Authors:  Hao Jiang
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2020-04-15       Impact factor: 4.490

Review 8.  The Unexpected Noncatalytic Roles of Histone Modifiers in Development and Disease.

Authors:  Yann Aubert; Shaun Egolf; Brian C Capell
Journal:  Trends Genet       Date:  2019-07-10       Impact factor: 11.639

9.  Anlotinib suppresses MLL-rearranged acute myeloid leukemia cell growth by inhibiting SETD1A/AKT-mediated DNA damage response.

Authors:  Jinzhu Chen; Juan Feng; Zhihong Fang; Jing Ye; Qinwei Chen; Qiuling Chen; Kai Chen; Xiaoming Xiong; Guowei Li; Haihan Song; Bing Xu
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

10.  Targeted therapy for fusion-driven high-risk acute leukemia.

Authors:  Yana Pikman; Kimberly Stegmaier
Journal:  Blood       Date:  2018-07-26       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.